ReviewFrontiers in oncology2020
The Slippery Role of Induction Chemotherapy in Head and Neck Cancer: Myth and Reality.
Review in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Prospective study comparing acute toxicity and objective response rate between simultaneous integrated boost and sequential boost Intensity-Modulated radiation therapy for locally advanced head and neck squamous cell carcinoma.Medical oncology (Northwood, London, England) · 2025Trial
- BMI and PNI as predictors of treatment completion and survival in locally advanced HNSCC receiving sequential chemoradiotherapy.BMC cancer · 2025Article
- Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy.Scientific reports · 2025Article
- Response to Induction Chemotherapy as a Predictor of Clinical Outcome After Chemoradiation in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients: A Retrospective Study.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2025Article
- Treatment-related mortality in head and neck cancer patients receiving chemotherapy and radiation: results of a meta-analysis of published trials.Therapeutic advances in medical oncology · 2025Article
- Outcomes of definitive radiotherapy vs. laryngectomy followed by adjuvant radiotherapy in patients with locally advanced laryngeal squamous cell carcinoma: real-world experience in a referral cancer center.Radiation oncology (London, England) · 2024Article
- Comprehensive review of post-treatment imaging in head and neck cancers: from expected to unexpected and beyond.The British journal of radiology · 2024Review
- Clinical prognostic factors to guide treatment strategy for HPV‑positive oropharyngeal cancer using treatment outcomes of induction chemotherapy: A real‑world experience.Oncology letters · 2024Article
- Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis.BMC complementary medicine and therapies · 2024Article
- Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced sinonasal squamous cell carcinoma.Frontiers in oncology · 2024Article
- Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy.Clinical Medicine Insights. Oncology · 2024Article
- Chitosomes Loaded with Docetaxel as a Promising Drug Delivery System to Laryngeal Cancer Cells: An In Vitro Cytotoxic Study.International journal of molecular sciences · 2023Article
- Suppression of TLR signaling by IRAK-1 and -4 dual inhibitor decreases TPF-resistance-induced pro-oncogenic effects in HNSCC.3 Biotech · 2023Article
- Interval changes of histogram-derived diffusion indices predict treatment response to induction chemotherapy in head and neck cancer: a feasibility study.Quantitative imaging in medicine and surgery · 2022Article
- Article
- De-Escalation Strategies for Human Papillomavirus-Associated Oropharyngeal Squamous Cell Carcinoma-Where Are We Now?Current oncology (Toronto, Ont.) · 2022Review
- Insights into Nanomedicine for Head and Neck Cancer Diagnosis and Treatment.Materials (Basel, Switzerland) · 2022Review
- Extraction parameter optimized radiomics for neoadjuvant chemotherapy response prognosis in advanced nasopharyngeal carcinoma.Clinical and translational radiation oncology · 2022Article
- Review
- Predictive Biomarkers for Response and Toxicity of Induction Chemotherapy in Head and Neck Cancers.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoradiotherapy as an alternative to surgery can be offered to patients affected by loco-regionally advanced head and neck cancer (HNC). Induction chemotherapy is a valid option, supported by few positive trials, but its real efficacy is still a matter of debate. The standard regimen for induction chemotherapy in Europe is a combination of docetaxel (75 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.